Tumor response and survival in patients with advanced non-small-cell lung cancer: the predictive value of chemotherapy-induced changes in fibrinogen
详细信息 查看全文
- 作者：Jun Zhao (1)
Mingfang Zhao (1)
Bo Jin (1)
Ping Yu (1)
Xuejun Hu (1)
Yuee Teng (1)
Jingdong Zhang (1)
Ying Luo (1)
Lingyun Zhang (1)
Shuang Zheng (1)
Qiyin Zhou (1)
Heming Li (1)
Yunpeng Liu (1)
Xiujuan Qu (1) - 关键词：Hyperfibrinogenemia ; Biomarker ; NSCLC
- 刊名：BMC Cancer
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：12
- 期：1
- 全文大小：389KB
- 参考文献：1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH, Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advaced non-small cell lung cancer. / N Eng J Med 2002,346(2):92-8. CrossRef
2. Ardizzoni A, Boni L, Tiseo M: Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. / J Natl Cancer Inst 2007,99(11):847-57. CrossRef
3. Rosell R, Lord R, Taron M, Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. / Lung Cancer 2002, 38:217-27. CrossRef
4. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC, IALT Bio Investigators: DNA repair by ERCCI in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. / The New Engl J Med 2006, 355:983-91. CrossRef
5. Ryu JS, Shin ES, Nam HS, Yi HG, Cho JH, Kim CS, Kim HJ, Lee JE: Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. / J Thorac Oncol 2011, 6:1320-329. CrossRef
6. Altiay G, Ciftci A, Demir M, Kocak Z, Sut N, Tabakoglu E, Hatipoglu ON, Caglar T: High plasma D-dimer level is associated with decreased survival in patients with lung cancer. / Clin Oncol (R Coll Radiol) 2007, 19:494-98. CrossRef
7. Batschauer A, Figueiredo C, Bueno E, Ribeiro M, Dusse L, Fernandes A, Gomes K, Carvalho M: D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer. / Ann Oncol 2010, 21:1267-272. CrossRef
8. Dirix LY, Salgado R, Weytjens R, Colpaert C, Benoy I, Huget P, van Dam P, Prové A, Lemmens J, Vermeulen P: Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer. / Br J Cancer 2002, 86:389-95. CrossRef
9. Kwon H, Oh S, Lee S, Kim S, Han JY, Koh RY, Kim MC, Kim H: Plasma Levels of Prothrombin Fragment F1 + 2, D-dimer and Prothrombin Time Correlate with Clinical Stage and Lymph Node Metastasis in Operable Gastric Cancer Patients. / Jpn J Clin Oncol 2008, 38:2-. CrossRef
10. Kilic M, Yoldas O, Keskek M, Ertan T, Tez M, Gocmen E, Koc M: Prognostic value of plasma D-dimer levels in patients with colorectal cancer. / Colorectal Dis 2008, 10:238-41. CrossRef
11. Pedersen L, Milman N: Prognostic significance of thrombocytosis in patients with primary lung cancer. / Eur Resp J 1996, 9:1826-830. CrossRef
12. Tennent GA, Brennan SO, Stangou AJ, Grady JO, Hawkins PN, Pepys MB: Human plasma fibrinogen is synthesized in the liver. / Blood 2007, 109:1971-974. CrossRef
13. Weisel JW: Fibrinogen and fibrin. / Adv Protein Chem 2005, 70:247-99. CrossRef
14. Brown LF, Water L, Harvey VS, Dvorak HF: Fibrinogen Influx and Accumulation of Cross-linked Fibrin in Healing Wounds and in Tumor Stroma. / Am J Pathol 1988, 130:455-65.
15. Jensen T, Kierulf P, Sandset P, Klingenberg O, Godal H: Fibrinogen and fibrin induce synthesis of pro- inflammatory cytokines from isolated peripheral blood mononuclear cells. / Thromb Haemost 2007, 20:822-29.
16. Ferrigno D, Buccheri G, Ricca I: Prognostic significance of blood coagulation tests in lung cancer. / Eur Resp J 2001, 17:667-73. CrossRef
17. Buccheri G, Ferrigno C, Ginardi , Zuliani C: Haemostatic Abnormalitities in Lung Cancer: Prognosic Implications. / Eur J Cancer 1997, 33:50-5. CrossRef
18. Jones J, McGonigle N, McAnespie M, Cran G, Graham A: Plasma fibrinogen and serum C-reactive protein are associated with non-small cell lung cancer. / Lung Cancer 2006, 53:97-01. CrossRef
19. Guo Q, Zhang B, Dong X: Elevated Levels of Plasma Fibrinogen in Patients With Pancreatic Cancer. / Pancreas 2009, 38:75-9. CrossRef
20. Yamashita H, Kitayama J, Nagawa H: Hyperfibrinogenemia is a Useful Predictor for Lymphatic Metastasis in Human Gastric Cancer. / Jpn J Oncol. 2005, 35:595-00. CrossRef
21. Yamashita H, Kitayama J, Kanno N, Yatomi Y, Nagawa H: Hyperfibrinogenemia is associated with lymphatic as well as hematogenous metastasis and worse clinical outcome in T2 gastric cancer. / BMC Cancer 2006, 6:147. CrossRef
22. Tang L, Liu K, Wang J, Wang C, Zhao P, Liu J: High Preoperative Plasma Fibrinogen Levels Are Associated With Distant Metastases and Impaired Prognosis After Curative Resection in Patients With Colorectal Cancer. / J of Sur Oncol 2010, 102:428-32. CrossRef
23. Takeuchi H, Ikeuchi S, Kitagawa Y, Shimada A, Oishi T, Isobe Y, Kubochi K, Kitajima M, Matsumoto S: Pretreatment plasma fibrinogen level correlates with tumor progression and metastasis in patients with squamous cell carcinoma of the esophagus. / J Gastroenterol Hepatol 2007, 22:2222-227. CrossRef
24. Seebacher V, Polterauer S, Grimm C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L: The prognostic value of plasma fibrinogen levels in patients with endometrial cancer: a multi-centre trial. / Br J Cancer 2010, 102:952-56. CrossRef
25. Polterauer S, Grimm C, Seebacher V, Concin N, Marth C, Tomovski C, Husslein H, Leipold H, Hefler-Frischmuth K, Tempfer C, Reinthaller A, Hefler L: Plasma Fibrinogen Levels and Prognosis in Patients with Ovarian Cancer: A Multicenter Study. / Oncologist 2009, 14:979-85. CrossRef
26. Polterauer S, Seebacher V, Hefler-Frischmuth K, Grimm C, Heinze G, Tempfer C, Reinthaller A, Hefler L: Fibrinogen plasma levels are an independent prognostic parameter in patients with cervical cancer. / Am J Obstet Gynecol 2009, 200:647-48. CrossRef
27. Kawai K, Kitayama J, Tsuno NH, Sunami E, Nagawa H: Hyperfibrinogenemia after preoperative chemoradiotherapy predicts poor response and poor prognosis in rectal cancer. / Int J Colorectal Dis 2011, 26:45-1. CrossRef
28. Milroy R, Douglas JT, Campbell J, Carter R, Dolowe G, Banham SW: Abnormal haemostasis in small cell lung cancer. / Thorax 1988, 43:978-81. CrossRef
29. Meehan KR, Zacharski LR, Moritz TE, Rickles FR: Pretreatment fibrinogen levels are associated with response to chemotherapy in patients with small cell carcinoma of the lung: Department of Veterans Affairs Cooperative Study 188. / Am J Hematol 1995, 49:143-48. CrossRef
30. Zecchina G, Ghio P, Bosio S, Cravino M, Camaschella C, Scagliotti G: Reactive thrombocytosis might contribute to chemotherapy-related thrombophilia in patients with lung cancer. / Clin Lung Cancer 2007, 8:264-70. CrossRef
31. Fidller I, Ellis L: The implication of angiogenesis for the biology and therapy of cancer metastasis. / Cell 1994, 79:315-28. CrossRef
32. Wang X, Wang E, Kavanagh J, Freedman R: Ovarian cancer, the coagulation pathway, and inflammation. / J Transl Med 2005, 3:25. CrossRef
33. Fearon K, Barber M, Falconer J, McMillan D, Ross J, Preston T: Pancreatic cancer as a model: inflammatory mediators, acute-phase response, and cancer cachexia. / World J Surg 1999, 23:584-88. CrossRef
34. Amrani D: Regulation of fibrinogen biosynthesis: glucocorticoid and interleukin-6 control. / Blood Coagul Fibrinolys 1990, 1:443-46. CrossRef
35. Zhang Z, Fuller G: Interleukin 1beta inhibits interleukin 6-mediated rat gamma fibrinogen gene expression. / Blood 2000, 96:3466-472.
36. Kulpa J, Wójcik E, Reinfuss M, Ko?odziejski L: Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-, and neuron-specific enolase in squamous cell lung cancer patients. / Clin Chem 2002, 48:1931-937.
37. Ardizzoni A, Cafferata MA, Tiseo M, Filiberti R, Marroni P, Grossi F, Paganuzzi M: Decline serum carcinomebryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced non small cell lung cancer. / Cancer 2006, 107:2842-849. CrossRef
38. Susana C, Isaac N, Marina L, Pablo M, Eva C, Davis T, Enriqueta F: Serum Tumor Markers CEA, CYFRA21-, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC). / Clin Lung Cancer 2011, 12:172-79. CrossRef
39. Trapé J, Buxo J, Pérez De Olaguer J, Vidal C: Tumor markers as prognostic factors in treated non-small cell lung cancer. / Anticancer Res 2003, 23:4277-281.
40. Jin B, Huang AM, Zhong RB, Han BH: The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer. / Chemotherapy 2010, 56:417-23. CrossRef
41. Arrieta O, Saavedra-Perez D, Kuri R, Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga A, Guzman E, De la Garza J: Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced nonsmall cell lung cancer: a prospective analysis. / BMC Cancer 2009, 9:119. CrossRef
42. Za?eska M, Szturmowicz M, Zych J, Roszkowska-Sliz B, Demkow U, Langfort R, Roszkowski-Sliz K: Elevated serum NSE level in locally advanced and metastatic NSCLC predispose to better response to chemotherapy but worse survival. / Pneumonol Alergol Pol 2010, 78:14-0.
43. American Thoracic Society and European Respiratory Society: Pretreatment evaluation of non-small cell lung cancer. / Am J Respir Crit Care Med 1997, 156:320-32.
44. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/330/prepub - 作者单位：Jun Zhao (1)
Mingfang Zhao (1)
Bo Jin (1)
Ping Yu (1)
Xuejun Hu (1)
Yuee Teng (1)
Jingdong Zhang (1)
Ying Luo (1)
Lingyun Zhang (1)
Shuang Zheng (1)
Qiyin Zhou (1)
Heming Li (1)
Yunpeng Liu (1)
Xiujuan Qu (1)
1. Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China - ISSN：1471-2407
文摘
Background Hyperfibrinogenemia is a common problem associated with various carcinomas, and is accompanied by hypercoagulablity. In advanced non-small-cell lung cancer (NSCLC) it remains unclear whether or not chemotherapy-induced changes in fibrinogen level relate to chemotherapeutic response and prognosis. The purposes of this study were to: 1) analyze the association between chemotherapy-induced changes in plasma fibrinogen level and the chemotherapeutic response after the first two courses of standard first-line platinum-based chemotherapy; and 2) evaluate the prognostic significance of the basal plasma fibrinogen level in patients with advanced NSCLC. Methods In this retrospective study, the data from 160 patients with advanced NSCLC were collected. The association between the changes in fibrinogen and the response to chemotherapy, or between the pre-and post-chemotherapy fibrinogen levels and patient clinical characteristics, were analyzed using SPSS software. In addition, the prognostic value of pre-chemotherapy fibrinogen levels was assessed. Results The median pre-chemotherapy plasma fibrinogen level was 4.4 g/L. Pre-chemotherapy plasma fibrinogen levels correlated significantly with gender (p = 0.041). Post-chemotherapy plasma fibrinogen levels correlated with gender (p = 0.023), age (p = 0.018), ECOG (p = 0.002) and tumor response (p = 0.049). Plasma fibrinogen levels markedly decreased after chemotherapy in 98 (61.25 %) patients with pre-chemotherapy hyperfibrinogenemia (p = 0.008); and in this population there was a significant link between the decrease in fibrinogen level, and initial partial response (PR; p = 0.017) and stable disease (SD; p = 0.031). Univariate and multivariate analysis revealed that higher levels of fibrinogen (?.4 g/L) and ECOG 1 were positively associated with shorter overall survival (OS). CEA and CA125 also decreased significantly (p =0.015, p =0.000) in DCR group after chemotherapy. Conclusions This study showed that the reduction in plasma fibrinogen levels induced by chemotherapy might be as a promising biomarker as CEA and CA125 for evaluating the efficacy of chemotherapy in advanced NSCLC. In addition, basal plasma fibrinogen levels could be used as an independent prognostic parameter for the OS of patients with advanced NSCLC.